Effect of COVID-19 pandemic on glaucoma surgical practices in the UK

Background/Aim The aim of the study was to examine the effect of the COVID-19 pandemic on glaucoma surgical practices within the UK. Methods A cross-sectional online survey was distributed to all consultant glaucoma specialists who are on the UK and Eire Glaucoma Society contact list. Participants were asked specific questions regarding preferences in glaucoma surgical practices and whether these had changed subsequent to the onset of the COVID-19 pandemic. Results Trabeculectomy was the procedure of choice for 61 (87%) glaucoma specialists. A total of 51 (73%) respondents reported performing minimally invasive glaucoma surgery (MIGS) procedures before the COVID-19 pandemic. The most commonly performed MIGS procedure was the iStent inject (51%), followed by XEN 45 (36%) and Preserflo (17%). Forty-three (61%) respondents reported modifying their glaucoma surgery practice subsequent to the onset of the COVID-19 pandemic. Of the glaucoma specialists who modified their surgical practices, 21 (43%) specifically reduced the number of trabeculectomies performed. In combination, diode laser (both micropulse and conventional trans-scleral cyclodiode) was the most common alternative procedure. Glaucoma drainage devices, deep sclerectomy and Preserflo were also commonly chosen alternatives. Conclusion Although trabeculectomy remains the most commonly performed established glaucoma surgery, it is being performed with reduced frequency during the COVID-19 pandemic due to the number of postoperative visits and procedures required. Alternatives such as conventional and micropulse diode laser, glaucoma drainage devices, deep sclerectomy and Preserflo appear to be the favoured alternative procedures.

[1]  Poemen P. Chan,et al.  Treatment Outcomes Using the PAUL Glaucoma Implant to Control Intraocular Pressure in Eyes with Refractory Glaucoma. , 2020, Ophthalmology. Glaucoma.

[2]  L. Quaranta,et al.  Glaucoma Surgery During the COVID-19 Pandemic in Italy: How Novel Coronavirus has Changed the Surgical Management of Glaucoma Patients. , 2020, Journal of glaucoma.

[3]  N. Kumaran,et al.  Part 2 model eye simulation: aerosol generating procedures in intraocular surgery , 2020, Eye.

[4]  T. Dada,et al.  Preferred practice guidelines for glaucoma management during COVID-19 pandemic , 2020, Indian journal of ophthalmology.

[5]  N. Kumaran,et al.  Aerosol generating procedures in intraocular surgery , 2020, Eye.

[6]  J. Liebmann Ophthalmology and Glaucoma Practice in the COVID-19 Era , 2020, Journal of glaucoma.

[7]  M. Schlenker,et al.  Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt with Mitomycin C. , 2020, American journal of ophthalmology.

[8]  P. Bloom,et al.  Micropulse transscleral cyclophotocoagulation: initial results using a reduced energy protocol in refractory glaucoma , 2020, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  W. Feuer,et al.  Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. , 2018, Ophthalmology.

[10]  N. Anand,et al.  Deep sclerectomy for uveitic glaucoma: long-term outcomes , 2017, Eye.

[11]  N. Anand,et al.  Outcomes of combined phacoemulsification and deep sclerectomy: a 10-year UK single-centre study , 2015, Eye.

[12]  A. Gupta,et al.  Primary Phakic Deep Sclerectomy Augmented With Mitomycin C: Long-term Outcomes , 2011, Journal of glaucoma.